Traduction de «com more information is available » (Néerlandais → Français) :

To learn more about our commitments, please visit us at www.pfizer.com. More information is available at www.pfizer.com.
To learn more about our commitments, please visit us at www.pfizer.com .More information is available at www.pfizer.com.

Exelon/Exelon Patch (USD 954 million, +22% lc), a therapy for mild to moderate forms of Alzheimer’s disease dementia as well as dementia linked with Parkinson’s disease, achieved more than half of its sales from Exelon Patch, the novel skin patch launched in late 2007 that is now available in more than 60 countries worldwide.
Exelon/Exelon Patch (USD 954 millions, +22% en m. l) est un traitement des formes légères à modérées de la maladie d'Alzheimer et de la démence associée à la maladie de Parkinson. Plus de la moitié des ventes est réalisée par Exelon Patch, une nouvelle formulation de patch transdermique lancée fin 2007 et désormais disponible dans plus de 60 pays.

Exelon/Exelon Patch (USD 687 million, +24 % lc), a therapy for mild to moderate forms of Alzheimer’s disease dementia as well as dementia linked with Parkinson’s disease, now achieves more than half of its sales from Exelon Patch, the novel skin patch launched in late 2007 and now available in more than 50 countries worldwide.
Exelon/Exelon Patch (USD 687 millions, +24% en m. l.), traitement des formes légères à modérées de la maladie d'Alzheimer et de la démence associée à la maladie de Parkinson, a bénéficié du lancement à fin 2007 d’Exelon Patch, une nouvelle formulation de patch transdermique, qui est désormais disponible dans plus de 50 pays.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:
More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com , including copies of:

While close to 95% of the items on the World Health Organization’s (WHO) list of essential medicines are available at reduced, off-patent prices, more than a third of the world’s population still has no access to them.
Un seul exemple illustre ce phénomène : à l’heure actuelle, un tiers de la population mondiale reste privée des traitements médicaux de base, alors que près de 95% des articles placés par l’OMS sur sa liste des médicaments essentiels sont disponibles hors brevets, à des prix réduits.

Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today. Participants are advised to pre-register in advance of the conference call.
Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Also, men were more likely to regularly discuss options for information or support(26 percent versus 14 percent)
Also, men were more likely to regularly discuss options for information or support [26 percent versus 14 percent]

For more information, call toll-free 866-AFA-8484 or visit www.alzfdn.org.
For more information, call toll-free 866-AFA-8484 or visit www.alzfdn.org .

For more information about Eisai, please visit www.eisai.com.
For more information about Eisai, please visit www.eisai.com .